Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A3CL
|
|||
| Former ID |
DIB001791
|
|||
| Drug Name |
AZD1979
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H26N4O5
|
|||
| Canonical SMILES |
COC1=CC=C(C=C1)C2=NN=C(O2)C(=O)N3CC(C3)OC4=CC=C(C=C4)CN5CC6(C5)COC6
|
|||
| InChI |
1S/C25H26N4O5/c1-31-19-8-4-18(5-9-19)22-26-27-23(34-22)24(30)29-11-21(12-29)33-20-6-2-17(3-7-20)10-28-13-25(14-28)15-32-16-25/h2-9,21H,10-16H2,1H3
|
|||
| InChIKey |
BKKPIQPFRAPEAY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1254035-84-1
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:139154
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanin-concentrating hormone receptor 1 (MCHR1) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02072993) A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males. U.S. National Institutes of Health. | |||
| REF 2 | Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.